Business
Blackstone Life Sciences Invests $250 Million in Anagram Therapeutics to Advance Novel and Patient-Friendly Oral Enzyme Replacement Therapy for Pancreatic Insufficiency
NEW YORK & NATICK, Mass., May 07, 2026--Blackstone Life Sciences ("BXLS") today announced a $250 million investment in Anagram Therapeutics ("Anagram"), a clinical-stage private biopharmaceutical company dedicated to improving the lives of people living with exocrine pancreatic insufficiency due to cystic fibrosis ("CF"), pancreatic cancer and related disorders. The investment will help fund the further development, approval and launch of Anagram’s ANG003, a novel orally delivered recombinant en
About this update from Blackstone Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1651,"height":646,"url":"https://media.zenfs.com/en/business-wire.com/e8d04dc64ccf0a55f87196efff6cfcbb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RY.OrOvh7dMdc71Nyv9FmQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM3Ng--/https://media.zenfs.com/en/business-wire.com/e8d04dc64ccf0a55f87196efff6cfcbb","width":960,"height":376},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/njnpxkWT61O7dOQWaJbnVw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTI1MA--/https://media.zenfs.com/en/business-wire.com/e8d04dc64ccf0a55f87196efff6cfcbb","width":640,"height":250},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/_FKTqD6b5tudYYRrnq04MQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NDA-/https://media.zenfs.com/en/business-wire.com/e8d04dc64ccf0a55f87196efff6cfcbb","width":1200,"height":470}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/ee49ccf107a38d324110a27479ca8ad7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/q3h7G6UWq8yM6W6K4gzgHg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/ee49ccf107a38d324110a27479ca8ad7","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/tdcP3zGPzB_AHqT_7TU3oQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/ee49ccf107a38d324110a27479ca8ad7","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/bSVfKBaqtT8CS3jyK29MLA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/ee49ccf107a38d324110a27479ca8ad7","width":1024,"height":512}}},{"type":"text","content":"People with exocrine pancreatic insufficiency currently face highly disruptive pill burden – ANG003 expected to only require one tablet per meal","length":144,"tagName":"p"},{"type":"text","content":"NEW YORK & NATICK, Mass., May 07, 2026--(BUSINESS WIRE)--Blackstone Life Sciences ("BXLS") today announced a $250 million investment in Anagram Therapeutics ("Anagram"), a clinical-stage private biopharmaceutical company dedicated to improving the lives of peop...